|1.||Amin, Mahul B: 6 articles (07/2014 - 01/2003)|
|2.||Lopez-Beltran, Antonio: 5 articles (07/2014 - 04/2008)|
|3.||Shen, Steven S: 4 articles (07/2014 - 01/2011)|
|4.||Cheng, Liang: 3 articles (07/2014 - 04/2008)|
|5.||Ro, Jae Y: 3 articles (07/2014 - 01/2013)|
|6.||Paner, Gladell P: 3 articles (07/2014 - 02/2013)|
|7.||Hansel, Donna E: 3 articles (07/2014 - 11/2012)|
|8.||Oliva, Esther: 3 articles (01/2005 - 01/2003)|
|9.||Wu, X R: 3 articles (06/2001 - 11/2000)|
|10.||Sun, T T: 3 articles (06/2001 - 11/2000)|
01/01/2015 - "Log-rank tests indicated high serum uroplakin III to be significantly associated with cancer-specific mortality. "
11/01/2014 - "UP III Positivity for uroplakin III is not found only in primary bladder UC variants, but in some tumors that have metastatized to the bladder. "
07/01/2014 - "Pathologists have used the uroplakin III antibody (AU1) to identify tumors of urothelial origin; however, the use of AU1 is limited because of its poor sensitivity. "
01/01/2014 - "Uroplakin III, CK20, and CK7 immunohistochemistry was performed to confirm the urothelial origin of urethral tumors. "
02/15/2013 - "Uroplakin III was expressed in 19 of 20 primary tumors and 17 of 17 ABWTCCs. "
|2.||Renal Cell Carcinoma (Grawitz Tumor)
01/01/2005 - "Urothelial markers (thrombomodulin and uroplakin III) and renal cell carcinoma markers (CD10 and renal cell carcinoma marker) can be helpful in the diagnosis of metastatic urothelial and renal cell tumors to the ovary. "
01/01/2014 - "Stains for cell adhesion molecule 5.2 (CAM 5.2), CD117, cytokeratin 20 (CK20), human melanoma black 45 (HMB-45), paired box protein (PAX 8), placental alkaline phosphatase (PLAP), prostate specific antigen (PSA), renal cell carcinoma (RCC), cancer antigen 25 (CA25), leukocyte common antigen (LC), S-100 protein, and uroplakin III were all negative. "
01/01/2015 - "In this study, preoperative serum levels of uroplakin III were measured in patients with urothelial carcinoma of the urinary bladder and examined for possible association with clinicopathological features and clinical outcomes. "
11/01/2014 - "Value of uroplakin III in distinguishing variants of primary bladder urothelial carcinoma from malignancy metastatic to the urinary bladder."
11/01/2012 - "When interpreted in correlation with clinical history and histomorphology, a panel of immunostains including CK7, CK20, GATA-3, CK14, desmoglein-3, and uroplakin III may be a useful adjunct in the distinction of metastatic urothelial carcinoma to the lung."
01/01/2008 - "Namely, in human bladder carcinoma cells, cooperation of uroplakin III and Src, both of which localize to the membrane microdomains, allows cells to escape from apoptotic cell death and proliferate under culture conditions deprived of serum. "
06/01/2006 - "To investigate the association between the expression of uroplakin III (UPIII) and the prognosis of patients with urothelial carcinoma of the upper urinary tract, as uroplakins are urothelium-specific markers of terminal urothelial differentiation. "
|4.||Neoplasm Metastasis (Metastasis)
07/01/2013 - "The purpose of this study was to characterize the clinical and histologic features of cutaneous TCC metastasis, confirmed by uroplakin-III immunohistochemistry, in dogs. "
06/01/2013 - "The neoplastic population in the joints and prostate gland showed strong immunoreactivity to uroplakin III, a urothelial marker, indicating metastasis of a transitional cell carcinoma to multiple joints. "
05/01/2000 - "Uroplakin III was detected in 21 (60%) of the primary urothelial carcinomas and 17 (53%) of the metastases, resulting in an overall sensitivity of 0.57. "
01/01/1993 - "These results show that uroplakin III may serve as a useful marker for TCCs, revealing specific urothelial differentiation features to be expressed in such tumors even after metastasis. "
|5.||Urinary Bladder Neoplasms (Bladder Cancer)
05/01/2014 - "The aim of this present study was to examine the uroplakin III (UPIII) expression in homogenous group of non-muscle invasive bladder cancer and to correlate its value with clinico-pathological characteristics of patients and moreover with COX-2 expression and tumor infiltrating lymphocytes (TILs). "
01/01/2015 - "Determination of serum uroplakin III level could be valuable for identifying patients with biologically aggressive bladder cancer."
01/01/2015 - "There was a significant increase in serum uroplakin III levels in patients with bladder cancer as compared to healthy controls (p<0.05). "
01/01/2015 - "High expression level of preoperative serum Uroplakin III is associated with biologically aggressive bladder cancer."
05/01/2014 - "Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer."
|2.||Keratin-7 (Cytokeratin 7)
|3.||Keratin-20 (Cytokeratin 20)
|10.||Proteins (Proteins, Gene)